AzTrials
AzTrials

Inflammatory Bowel Disease (IBD)NCT07681895

Biophysical Assessments of Acupuncture Points in Inflammatory Bowel Disease

An observational study of Inflammatory Bowel Disease (IBD), run by Brigham and Women's Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record

Search all trials

Trial summary

Acupuncture points or acupoints are fundamental to the practice of acupuncture, yet their scientific basis remains unclear. According to traditional explanations of acupuncture, acupoints can become tender or more sensitive to pressure when there is an underlying disease of the body. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Inflammatory Bowel Disease (IBD)
How many people
100 participants
Where
No sites listed yet
Study dates
1 Jan 2027to 30 Mar 2028
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Adults with inflammatory bowel disease (IBD) and healthy control participants will be enrolled into the study from the Greater Boston area.

Who may be able to join

  • adults (age 18 years or older)
  • clinical diagnosis of ulcerative colitis or Crohn's disease
  • adults (age 18 years or older) in good health conditions

Who cannot join

  • any history of serious musculoskeletal or soft tissue injury of the lower and/or upper extremities
  • presence of scarring or tattoo on the lower and/or upper extremities
  • presence of serious cardiac diseases, severe dermatological conditions, peripheral neuropathy, infectious disease, psychological illnesses, or other serious co-morbidities (e.g., cancer)
  • prior history of colostomy or ileostomy
  • pregnancy
  • history of chronic inflammatory diseases, such as IBD
Show all 11Show fewer
  • severe digestive and/or intestinal conditions, such as irritable bowel syndrome (IBS)
  • any history of serious musculoskeletal or soft tissue injury of the lower and/or upper extremities
  • presence of scarring or tattoo on the lower and/or upper extremities
  • presence of serious cardiac diseases, severe dermatological conditions, peripheral neuropathy, infectious disease, psychological illnesses, or other serious co-morbidities (e.g., cancer)
  • pregnancy

About this study

Official title: Acupoint Sensitization in Inflammatory Bowel Disease: A Non-interventional Study

Acupuncture points or acupoints are fundamental to the practice of acupuncture, yet their scientific basis remains unclear. According to traditional explanations of acupuncture, acupoints can become tender or more sensitive to pressure when there is an underlying disease of the body. Findings from recent basic animal studies support this traditional theory. For example, compared to healthy control animals, models of colitis have shown increased skin temperature, blood flow, and pain sensitivity at specific body regions that correspond to the location of acupoints that are commonly used in acupuncture treatment for colitis. However, little is known about whether these findings apply to humans.

Read the detailed description

Acupuncture is broadly understood as a technique in which practitioners stimulate specific points on the body - most often by inserting thin needles through the skin. Accordingly, acupuncture is theorized to "work" or provide therapeutic benefits through stimulation of specific points, collectively referred to as acupoints. However, to date, there is no clear scientific characterization of acupoints based on an objective, biomedical understanding of the body, which limits our understanding of how acupuncture works in a fundamental way.

Recent findings from basic animal studies suggest that cutaneous neurogenic inflammation may be a potential physiological correlate of acupoints, in the context of visceral diseases. Neurogenic inflammation refers to the role of sensory nerves in promoting inflammation and is mediated by neuropeptides released from the peripheral afferent terminals. Through interactions with nearby immune cells and endothelial cells, these neuropeptides promote increased levels of inflammatory mediators and induce vasodilation and plasma extravasation at the site of their release. In basic animal studies, Evans blue (EB) dye is typically used as a marker for microvascular leakage to assess the location and extent of neurogenic inflammation.

Using EB dye, several studies have provided compelling evidence that experimentally induced visceral diseases (e.g., rodent models of colitis, cystitis, gastritis) cause cutaneous neurogenic inflammation. In many of these studies, neurogenic inflammation was shown to manifest as discrete spots on certain body regions, corresponding to the locations of specific acupoints.

To date, little to no studies have been done to validate the aforementioned preclinical findings in human subjects. To bridge this gap, in this study, we will conduct clinical and translational (C/T) research in human subjects, using inflammatory bowel disease (IBD) as the disease model. We will compare measures of cutaneous sensitization in IBD patients and healthy control participants. Key features of neurogenic inflammation include increased blood flow, increased temperature, and pain sensitivity, so we will assess cutaneous blood perfusion, temperature, and pressure pain threshold (PPT) as proxy measures, using laser speckle contrast imaging (LSCI), infrared thermography, and pressure algometry, respectively.

Keywords
Inflammatory bowel disease, IBD, Acupuncture point, Acupoint, Cutaneous neurogenic inflammation, Infrared thermography, Laser speckle contrast imaging, Pressure pain threshold
Medical subject headings
Inflammatory Bowel Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07681895
Study groupRoleWhat they receive
IBDAdults with inflammatory bowel disease (IBD). This is a non-interventional study, involving noninvasive biophysical assessments of the skin in adults with IBD vs. healthy control participants.
ControlHealthy control participants. This is a non-interventional study, involving noninvasive biophysical assessments of the skin in adults with IBD vs. healthy control participants.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Skin blood perfusion

    Comparisons of cutaneous blood perfusion at predefined regions or points of interest between IBD patients and healthy control participants, as measured by laser speckle contrast imaging (LSCI). LSCI is a non-invasive imaging technique for assessing superficial tissue blood perfusion.

    Measured: 1 day

  2. Skin temperature

    Comparisons of skin temperature at predefined regions or points of interest between IBD patients and healthy control participants, as measured by infrared thermography.

    Measured: 1 day

  3. Pressure pain threshold

    Comparisons of pressure pain threshold (PPT) at predefined points of interest between IBD patients and healthy control participants, as measured by pressure algometry.

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jul 2026
  2. Study start1 Jan 2027 (estimated)
  3. Primary completion30 Jan 2028 (estimated)
  4. Study completion30 Mar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07681895
Sponsor's protocol ID
2025P002489
Other IDs
1K23AT013401-01
Status last verified
Oct 2026
First submitted
27 Jun 2026
Last updated
20 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in